Piperidine compounds, pharmaceutical composition comprising the same and its use
US-2016362374-A1 · Dec 15, 2016 · US
US10100011B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10100011-B2 |
| Application number | US-201515513072-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 22, 2015 |
| Priority date | Sep 23, 2014 |
| Publication date | Oct 16, 2018 |
| Grant date | Oct 16, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention relates to a novel pentadienoyl piperidine derivative, a pharmaceutical composition containing the same for prevention or treatment of metabolic diseases, and a functional food composition using the same for improvement or relief of metabolic diseases. The pentadienoyl piperidine derivative of the present invention inhibits the differentiation of preadipocytes, reduces body weight, visceral fat, blood lipid levels, and blood glucose levels, improves a blood liver function index, and suppresses metabolic inflammation responses. Thus, ultimately, the derivative can be usefully used as a medicine or a functional food composition, which exhibits the preventive or therapeutic activity for metabolic diseases selected from the group consisting of obesity, diabetes, dyslipidemia, fatty liver and insulin resistance syndrome.
Opening claim text (preview).
The invention claimed is: 1. A pentadienoyl piperidine derivative represented by Formula 1 below or a pharmaceutically acceptable salt thereof: wherein R 1 is a C 1 -C 3 alkyl group. 2. The pentadienoyl piperidine derivative or the pharmaceutically acceptable salt thereof according to claim 1 , wherein R 1 of Formula 1 is a methyl group. 3. A pharmaceutical composition for treatment of metabolic diseases, wherein the pharmaceutical composition comprises the pentadienoyl piperidine derivative or the pharmaceutically acceptable salt thereof according to claim 1 as an active ingredient and the metabolic diseases are selected from the group consisting of obesity, diabetes, dyslipidemia, fatty liver and insulin resistance syndrome. 4. The pharmaceutical composition according to claim 3 , wherein the dyslipidemia is hyperlipidemia. 5. The pharmaceutical composition according to claim 3 , wherein the fatty liver is non-alcoholic fatty liver. 6. The pharmaceutical composition according to claim 3 , wherein the composition reduces the differentiation of adipocytes. 7. The pharmaceutical composition according to claim 3 , wherein the composition reduces blood fat, liver fat or visceral fat. 8. The pharmaceutical composition according to claim 7 , wherein the visceral fat comprises one or more selected from the group consisting of epididymal fat, perirenal fat, mesenteric fat and retroperitoneal fat. 9. The pharmaceutical composition according to claim 3 , the composition reduces the activity of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) in blood. 10. A food composition for improvement or relief of metabolic diseases, wherein the food composition comprises the pentadienoyl piperidine derivative or the pharmaceutically acceptable salt thereof according to claim 1 as an active ingredient and the metabolic diseases are selected from the group consisting of obesity, diabetes, dyslipidemia, fatty liver and insulin resistance syndrome. 11. A method of improving or treating metabolic diseases, wherein the method comprises a step of administrating a composition comprising the pentadienoyl piperidine derivative or the pharmaceutically acceptable salt thereof according to claim 1 as an active ingredient to a subject in need and the metabolic diseases are selected from the group consisting of obesity, diabetes, dyslipidemia, fatty liver and insulin resistance syndrome.
for hyperglycaemia, e.g. antidiabetics · CPC title
by oxygen atoms · CPC title
only substituted in position 1, e.g. propipocaine, diperodon · CPC title
Anorexiants; Antiobesity agents · CPC title
Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.